AmCad BioMed Corporation

As of June 30, 2026, AmCad BioMed Corporation carries a market capitalization of 687.16M, placing it among publicly traded companies globally. Its enterprise value stands at 431.12M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, AmCad BioMed Corporation has 63.33M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 23.89, and the price-to-book ratio stands at 1.33.

These figures are as of June 30, 2026. The EV/Sales ratio of 15.07 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 431.12M versus a market cap of 687.16M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, AmCad BioMed Corporation maintains a current ratio of 18.49, meaning it holds 18.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 2.27, indicating elevated leverage, while an interest coverage ratio of -349.81 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, AmCad BioMed Corporation posted a negative return on equity (ROE) of -10.05, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -8.37, reflecting losses generated across the asset base. The company generates approximately 386,527.03 in revenue per employee across its workforce of 74.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.63 indicates how many times AmCad BioMed Corporation sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, AmCad BioMed Corporation recorded 12,000.00 in income tax expense. The company reported a pretax loss of -67.46M and -52.66M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, AmCad BioMed Corporation's stock has gained approximately 7.86% over the past 52 weeks. The 50-day moving average sits at 13.52, while the 200-day moving average is 12.51.

Over the twelve months ended June 30, 2026, AmCad BioMed Corporation generated 28.60M in revenue and converted that into -52.66M in net income, yielding earnings per share of -1.07. EBITDA reached -70.66M, while operating income came in at -86.67M.

As of June 30, 2026, AmCad BioMed Corporation holds 341.88M in cash and equivalents against 13.35M in total debt, resulting in a net debt position of -15.99M. Total book value stands at 515.55M, with working capital of 357.26M providing operational flexibility.

AmCad BioMed Corporation produced -47.31M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -120,000.00 in capital expenditures, free cash flow totaled -47.43M - equivalent to -0.75 per share.

Over the twelve months ended June 30, 2026, AmCad BioMed Corporation posted a gross margin of 36.13, reflecting its pricing power and cost economics. The operating margin of -303.03 and net profit margin of -184.10 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -6.94: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.69, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to AmCad BioMed Corporation shareholders.

AmCad BioMed Corporation's most recent stock split took place on July 1, 2024 with a 45:46 split ratio.

As of June 30, 2026, AmCad BioMed Corporation has an Altman Z-Score of 13.66, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.